Search research articles
Contact Us
Filters
Showing results (11-20 of 96) with videos related to
Page
of 10
Sort By:
Multiple Sclerosis and Related Disorders
|
November 17, 2017
Comparing the efficacy of disease-modifying therapies in multiple sclerosis
Dimos D Mitsikostas, Douglas S Goodin
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
September 25, 2014
Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation
Dimos D Mitsikostas, Christina I Deligianni
Current Opinion in Neurology
|
June 8, 2022
Therapies targeting CGRP signaling for medication overuse headache
Ioannis-Alexios Koumprentziotis, Dimos D Mitsikostas
BMC Medicine
|
November 12, 2015
New players in the preventive treatment of migraine
Dimos D Mitsikostas, Alan M Rapoport
Nature Reviews. Neurology
|
November 17, 2020
Making headway - a role for CGRP in post-traumatic headache
Dimos D Mitsikostas, Michael A Moskowitz
Handbook of Clinical Neurology
|
February 2, 2024
Evidence-based symptomatic treatment of migraine
Dimos D Mitsikostas, Thomas N Ward
Headache
|
July 24, 2010
Sleep and headache: the clinical relationship
Dimos D Mitsikostas, Alexandros Viskos, Dimitrios Papadopoulos
Multiple Sclerosis and Related Disorders
|
September 17, 2019
Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments
Panagiotis Gklinos, Dimitrios Papadopoulos, Dimos D Mitsikostas
Frontiers in Pharmacology
|
August 10, 2019
Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
Ioanna Spanou, Theodoros Mavridis, Dimos D Mitsikostas
Headache
|
September 12, 2019
Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?
Piero Barbanti, Gabriella Egeo, Dimos D Mitsikostas
Page
of 10
Search research articles
Search
Showing results (11-20 of 96) with videos related to
Sort By:
Page
of 10
Multiple Sclerosis and Related Disorders
|
November 17, 2017
Comparing the efficacy of disease-modifying therapies in multiple sclerosis
Dimos D Mitsikostas, Douglas S Goodin
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
September 25, 2014
Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation
Dimos D Mitsikostas, Christina I Deligianni
Current Opinion in Neurology
|
June 8, 2022
Therapies targeting CGRP signaling for medication overuse headache
Ioannis-Alexios Koumprentziotis, Dimos D Mitsikostas
BMC Medicine
|
November 12, 2015
New players in the preventive treatment of migraine
Dimos D Mitsikostas, Alan M Rapoport
Nature Reviews. Neurology
|
November 17, 2020
Making headway - a role for CGRP in post-traumatic headache
Dimos D Mitsikostas, Michael A Moskowitz
Handbook of Clinical Neurology
|
February 2, 2024
Evidence-based symptomatic treatment of migraine
Dimos D Mitsikostas, Thomas N Ward
Headache
|
July 24, 2010
Sleep and headache: the clinical relationship
Dimos D Mitsikostas, Alexandros Viskos, Dimitrios Papadopoulos
Multiple Sclerosis and Related Disorders
|
September 17, 2019
Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments
Panagiotis Gklinos, Dimitrios Papadopoulos, Dimos D Mitsikostas
Frontiers in Pharmacology
|
August 10, 2019
Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
Ioanna Spanou, Theodoros Mavridis, Dimos D Mitsikostas
Headache
|
September 12, 2019
Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?
Piero Barbanti, Gabriella Egeo, Dimos D Mitsikostas
Page
of 10